Fortrea Holdings Inc. has unveiled its financial forecasts for 2026, anticipating revenues to fall within the range of $2,550 million to $2,650 million. The company also expects adjusted EBITDA to be between $190 million and $220 million. A key aspect of this projection is the assumption that foreign exchange rates will remain constant from their levels at the close of 2025 throughout the forecast period. This guidance follows the release of the company's financial performance for the fourth quarter and the full year of 2025, which included a substantial non-cash goodwill impairment charge affecting its GAAP net income, even as adjusted figures indicated profitability.
The company, recognized as a promising small-cap stock by Wall Street analysts, recently saw its price target adjusted by Baird, a financial services firm. On February 27, Baird revised its target for Fortrea Holdings Inc. (FTRE) from $19 down to $16, while maintaining an 'Outperform' rating on the stock. This adjustment provides context to the market's ongoing evaluation of FTRE's future potential amidst its financial disclosures.
Fortrea Holdings Inc.'s detailed financial outlook for 2026 was disclosed on February 26. This projection is built on the critical premise that currency exchange rates will not fluctuate from their December 31, 2025, standings. Such an assumption is vital for multinational corporations like Fortrea, which are susceptible to foreign exchange volatility impacting their reported revenues and earnings.
Reviewing its 2025 performance, Fortrea reported fourth-quarter sales of $660.5 million and a full-year total of $2,723.4 million. A significant factor in the full-year results was a non-cash goodwill impairment of $797.9 million, which contributed to a GAAP net loss of $(986.2) million. However, when accounting for these specific charges, the adjusted net income stood at $40.4 million, and the adjusted EBITDA reached $189.9 million. By the end of 2025, the company's balance sheet showed $174.6 million in cash and cash equivalents, $1,066.3 million in gross debt, and a robust backlog of $7,728.0 million, alongside a trailing twelve-month book-to-bill ratio of 1.02x. These figures demonstrate the company's operational strength despite the non-cash write-downs.
Fortrea Holdings Inc. functions as a global contract research organization, offering extensive services in clinical development, trial management, pharmacology, and consulting. It serves pharmaceutical, biotechnology, and medical device companies, assisting them in advancing therapeutic innovations from the initial research stages through post-approval. The company's strategic focus and operational scope underscore its role in the healthcare ecosystem.